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Abstract
Objectives To assess the feasibility of the mono-exponential,
bi-exponential and stretched-exponential models in evaluating
response of breast tumours to neoadjuvant chemotherapy
(NACT) at 3 T.
Methods Thirty-six female patients (median age 53, range
32–75 years) with invasive breast cancer undergoing NACT
were enrolled for diffusion-weighted MRI (DW-MRI) prior to
the start of treatment. For assessment of early response, chang-
es in parameters were evaluated on mid-treatment MRI in 22
patients. DW-MRI was performed using eight b values (0, 30,
60, 90, 120, 300, 600, 900 s/mm2). Apparent diffusion coef-
ficient (ADC), tissue diffusion coefficient (Dt), vascular frac-
tion (ƒ), distributed diffusion coefficient (DDC) and alpha (α)
parameters were derived. Then t tests compared the baseline
and changes in parameters between response groups.
Repeatability was assessed at inter- and intraobserver levels.
Results All patients underwent baseline MRI whereas 22 le-
sions were available at mid-treatment. At pretreatment, mean
diffusion coefficients demonstrated significant differences be-
tween groups (p < 0.05). At mid-treatment, percentage in-
crease in ADC and DDC showed significant differences be-
tween responders (49 % and 43 %) and non-responders (21 %
and 32 %) (p = 0.03, p = 0.04). Overall, stretched-exponential
parameters showed excellent repeatability.
Conclusion DW-MRI is sensitive to baseline and early treat-
ment changes in breast cancer using non-mono-exponential
models, and the stretched-exponential model can potentially
monitor such changes.
Key points
• Baseline diffusion coefficients demonstrated significant dif-
ferences between complete pathological responders and
non-responders.
• Increase in ADC and DDC at mid-treatment can discrimi-
nate responders and non-responders.
• The ƒ fraction at mid-treatment decreased in responders
whereas increased in non-responders.
• The mono- and stretched-exponential models showed excel-
lent inter- and intrarater repeatability.
• Treatment effects can potentially be assessed by non-mono-
exponential diffusion models.
Keywords Breast carcinoma . Diffusion-weightedMRI .
Neoadjuvant treatment . Quantitative evaluation . Tumour
biomarkers
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Introduction
Neoadjuvant chemotherapy (NACT) has increasingly been
utilized in the treatment of breast cancer to enable breast-
conse rv ing su rge ry and improve re sec t ab i l i t y.
Approximately 80 % of patients have been found to respond
to NACT, but only 6–25 % of patients show complete patho-
logical response (pCR) [1–3]. Therefore, functional imaging
techniques have been investigated for the prediction of re-
sponse early after initiating therapy.
Diffusion-weighted magnetic resonance imaging (DW-
MRI) derives image contrast from the differences in the mo-
bility of water protons between tissues. DW imaging in breast
protocols generally involves the acquisition of images at two b
values to quantitatively determine the mono-exponential rela-
tionship between signal attenuation and b value. The apparent
diffusion coefficient (ADC) enables characterisation of le-
sions based on differences in water diffusivity which in turn
reflect tissue cellularity and integrity of membranes [4]. The
association with cellular density makes ADC ideal for moni-
toring cytotoxic responses [5].
However, it has been shown that the degree of signal atten-
uation in breast tissue becomes non-linear with increasing b
value. Bi-exponential signal decay has been observed over a
range of b values, where a small increase (0 − 200 s/mm2)
results in a steep reduction in the measured signal intensity.
This has been related to perfusion in the microcapillary circu-
lation (expressed as pseudo-diffusion coefficient Dp and vas-
cular fraction ƒ). The signal then attenuates more gradually
over the range of higher b values (>200 s/m2) enabling the
measurement of true tissue diffusivity (Dt). This phenomenon,
known as intravoxel incoherent motion (IVIM), enables the
separation of molecular diffusion from perfusion, provided
that a wide range of low and high b values are used [6].
Whilst the IVIM model has the advantage that its compo-
nents can be associated with distinct physical phenomena [7,
8], estimates of perfusion have not been fully investigated in
practice for the assessment of therapeutic response in breast
cancer.
To overcome the assumptions associated with the bi-
exponential model, Bennett et al. introduced the stretched-
exponential approach, which models the continuous distribu-
tion of diffusion compartments attenuating at different rates
(termed DDC, distributed diffusion coefficient). The plot of
the signal intensity vs. b value becomes characteristically
stretched, indicating deviation from the single exponential de-
cay. This is denoted by the parameter α, which provides a new
type of image contrast that relates to the degree of intravoxel
water diffusion heterogeneity ranging from 0 to 1. A numer-
ically high α index (i.e. α approaching 1) represents low
intravoxel heterogeneity indicative of mono-exponential dif-
fusion-weighted signal decay, whereas a numerically low α
index (i.e. approaching 0) represents a high degree of diffu-
sion heterogeneity exhibited asmulti-exponential signal decay
[9–11].
In general, these non-Gaussian diffusionmodels offer more
parameters, which provide a better fit to the diffusion data.
Preliminary studies suggest that multi-exponential models im-
plemented in tumours of the brain [12, 13], head and neck [14,
15], abdomen [16] and prostate [17–19] can offer additional
information on tissue heterogeneity, vascularity and cellularity
beyond ADC.
The purpose of this work was to assess the feasibility of
diffusion parameters obtained from the mono-exponential, bi-
exponential and stretched-exponential diffusion models in
evaluating response of breast tumours to NACT at 3 T.
Materials and methods
Patient population and study design
The local institutional review boards and ethics committees
approved this prospective study and written informed consent
was obtained from all patients.
Patients were eligible if they were at least 18 years of age,
had pathologically confirmed invasive breast cancer and were
undergoing NACT as a first line of treatment. Patients were
ineligible if they had poor renal or liver functions, allergy to
gadolinium-based contrast agents, metals implants or a
pacemaker.
Assuming a moderate effect size between the diagnostic
performance of diffusion parameters and response (effect
size = 0.6), a sample size of 19 patients would be needed to
Eur Radiol
yield a power of 80 % with 95 % confidence levels. Between
February 2014 and September 2015, 40 female patients (me-
dian age 55, range 32 − 75 years) presented with a palpable
lump and underwent core biopsies under ultrasound guidance
by an experienced radiologist in the outpatient clinic prior to
the start of treatment. According to our local protocol, patients
received six cycles of NACT. The regimen consisted of doce-
taxel 100 mg/m2 once every 21 days for three cycles, followed
by fluorouracil 500 mg/m2, epirubicin 100 mg/m2, with cy-
clophosphamide 500 mg/m2 (FEC) once every 21 days for
three cycles if the tumour was negative for human epidermal
growth factor 2 (HER2−) on biopsy. Two patients, however,
were started on weekly taxols for 12 weeks at a lower dose
because of their age, as studies show that weekly doses may
offer the same benefit with fewer side effects [20, 21]. They
subsequently received the FEC part of their treatment as de-
scribed. This combination was reversed with the HER2+ can-
cers. In addition, docetaxel was combined with the HER2-
targeted agent trastuzumab (Herceptin®; Genentech Inc.,
CA) in these patients for the last three cycles. This therapeutic
combination is based on the recommendation of the interna-
tional consensus conference for neoadjuvant systemic therapy
in primary breast cancer [1]. Patient and tumour characteristics
are summarized in Table 1.
MRI technique
All MR examinations were performed on a 3.0-T system
(MR750, GE Healthcare) with a dedicated eight-channel
breast array coil. The MRI protocol included T1- and T2-
weighted axial images, DWI and dynamic contrast-enhanced
(DCE) series (Table 2). DW-MRI was performed utilizing a
single-shot spin-echo echo planar imaging sequence at eight b
values (0, 30, 60, 90, 120, 300, 600 and 900 s/mm2).
Subsequently, DCE-MRI data was acquired using a
three-dimensional segmented k-space spoiled gradient-
echo technique. Five acquisitions were obtained before
contrast agent injection and then once every 10 s after
bolus injection of 0.1 mmol/kg of gadopentetate
dimeglumine (Magnevist, Bayer Schering, Berlin) for
8 min 7 s. The total examination time was approximately
25 min.
Patients underwent MR imaging before the start of che-
motherapy, after completion of three cycles and at the end
of therapy. For the purposes of assessing early response,
data from the baseline and midway scans only were
analysed. The baseline MRI was performed approximately
10 days after histological confirmation of malignancy
(range 7–11 days). The median time interval between pre-
treatment MRI and the start of therapy was 1 day (range
0–2).
The median interval between the third cycle of chemother-
apy and the second MRI was 21 days (range 15–22).
After completion of NACT, all patients received breast
and axillary surgery, radiotherapy and endocrine therapy
as appropriate.
Image analysis
Tumours were identified on the post-contrast T1-weighted
images by two breast radiologists in consensus (R.B,
F.J.G, Cambridge, UK) with 4 and 20 years of experience
in breast MRI. Lesion site, size, morphology (mass vs.
non-mass-like lesion), enhancement pattern (heteroge-
neous vs. homogeneous enhancement) and kinetic fea-
tures (curve type; type I (progressive), type II (plateau)
or type III (washout)) were recorded. For both mass and
non-mass-like lesion demarcation, the early subtracted
Table 1 Tumour characteristics and patient outcome
Characteristic Responder Non-responder
Age (median age, range) 51 (36−66) 53 (42−68)
Tumour size
<2 cm 0 1
2–5 cm 11 10
>5 cm 3 11
Morphology
Mass 13 12
Non-mass like 1 10
Tumour histology
Invasive ductal carcinoma 12 18
Papillary carcinoma 1 1
Mucinous 0 1
Medullary 1 0
Mixed carcinomaa 0 2
Histological grade
II 3 14
III 11 8
Oestrogen receptor (ER) statusb
Positive (+) 4 20
Negative (−) 10 2
HER-2/neu receptor statusc
Positive (+) 2 11
Negative (−) 12 11
Unless otherwise indicated, data are number of patients
a Histology showed invasive carcinoma ofmixed types; one of which was
mucinous and ductal type, and the other showing lobular growth pattern
with tubule formation classified as mixed lobular and ductal carcinoma
b Tumours were classified as oestrogen receptor positive (and progester-
one receptor positive) if more than 10 % of the cells were stained
positively
c Tumours were classified as human epidermal growth factor 2 (HER2)
positive when they scored 3+ at immunohistochemistry or when gene
amplification was observed with fluorescence in situ hybridization
(FISH)
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DCE images were used as reference where freehand re-
gions of interest (ROIs) were manually drawn on the im-
aging slice with the largest tumour dimension on the
b = 900 s/mm2 image by one radiologist (R.B). Care was
taken to avoid tumour borders and areas of necrosis.
Intraobserver variability was evaluated by redrawing the
ROIs 3 weeks after the initial measurements. A third ra-
diologist (O.A) with 3 years’ experience in breast MRI
manually reoutlined the tumours to assess the inter-rater
variability of measurements.
All readers were blinded to the pathological findings and
therapeutic responses.
Diffusion analyses were performed using in-house soft-
ware developed in MATLAB (The Mathworks, Natick,
MA). To enable comparison with previous DWI breast stud-
ies, the ADC was calculated from two b values (0, 900 s/
mm2). All b values were used for the stretched-exponential
and IVIM models. For the non-Gaussian models, data was
fitted using a non-linear least-squares approach. ROIs were
analysed on a voxel-wise basis and parameters were expressed
as means over the volumes measured. Parametric maps of
diffusion coefficients were generated. Details of the quantita-
tive diffusion models are provided in the supplementary ma-
terial. Percentage change in parameters was calculated as:
(Parametermid − Parameterpre)/Parameterpre × 100, where
Parameterpre and Parametermid are the baseline and mid-
treatment measurements respectively.
Histological analysis and response assessment
Histopathological assessment was performed after surgical
excision following the last cycle of chemotherapy. Tumour
type, grade, hormone-receptor status and HER2 expression
were obtained from reports of the core biopsies or surgical
specimens. Although molecular testing is prognostic, it is ex-
pensive and not widely available. Therefore according to
Onitilo et al. [22, 23], four immunohistochemical (IHC) cate-
gories have been identified on the basis of the hormonal-
receptor status (oestrogen and progesterone receptor ER,
PR) and HER2 overexpression. These groups are ER+PR+/
HER2−, ER+PR+/HER+, ER−PR−/HER2+ and ER−PR
−/HER2− (i.e. triple-negative breast cancers, TNBC).
Tumour response was assessed in the excision specimens
by expert pathologists. Three categories were defined: (i)
pathological complete response (pCR) with or without the
presence of ductal carcinoma in situ (DCIS); (ii) partial re-
sponse to therapy; ranging from minimal residual disease up
to greater than 50 % of tumour cellularity; and (iii) no evi-
dence of response. The last two categories were considered
pathological non-complete response (pNCR).
Statistical analysis
All statistics were calculated from the logarithm of the param-
eters, assessed for normality using the Shapiro–Wilk test and
Table 2 MRI sequence
parameters Parameters T2-weighted Diffusion-weighted
imaging
Contrast-enhanced
T1-weighted
Sequence SE 2D SS-EPI 3D SPGR
FOV (mm2) 350 × 350 350 × 350 350 × 350
Image matrix 384 × 256 128 × 128 512 × 512
Section thickness (mm) 4.0 4.0 2.8 (interpolated to 1.4)
b values (s/mm2) – 0, 30, 60, 90, 120, 300, 600, 900 –
Pixel size (mm2) 0.9 × 1.3 2.7 × 2.7 0.6 × 0.6
Fat suppression No Spatial-spectral water
excitation with water
spectral presaturation
Spatial-spectral
water excitation
Parallel acquisition
(ASSET factor)
No 2 2.5 (phase direction)
TR (ms) 4.6 5.0 7.1
TE (ms) 76.2 77.9 3.7
RF excitation (degrees) 111 90 12
No. of averages 1 5 0.5
Bandwidth (kHz) 62.5 250 125
No. of slices 38 40 112
Acquisition time 47 s 9 min 8 min 7 s
SE spin-echo, 2D SS-EPI 2-dimensional single-shot echo planar imaging, 3D SPGR 3-dimensional spoiled
gradient-recalled echo, FOV field of view, ASSET array coil spatial sensitivity encoding technique, TR repetition
time, TE echo time, RF radiofrequency
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back-transformed where appropriate [24]. The mean value ±
standard deviation of ADC and the non-Gaussian parameters
were reported.
The pretreatment characteristics between pCR and pNCR
were compared using the unpaired two-tailed t test.
The IHC subtypes were compared between response
groups at baseline using the Chi-squared test. The imag-
ing parameters across the four subtypes were also com-
pared using the one-way analysis of variance (ANOVA).
The correlation between the diffusion coefficients was
evaluated using Pearson’s correlation. Receiver operating
characteristics (ROC) curves were constructed to assess
the performance of parameters in differentiating between
pCR and pNCR, and areas under the curve (AUCs) were
compared.
Repeatability of the baseline measurements was assessed at
inter- and intraobserver levels using the intraclass correlation
coefficient (ICC).
Model comparisons were made using the corrected Akaike
information criterion (AICc), which imposes a penalty for
additional parameters in the model [25]. The AICc was com-
puted for the three models and averaged over all lesion voxels,
which was subsequently averaged over all subjects. Statistical
analyses were performed using the software SPSS (v. 21.0,
Chicago, IL). As this study is primarily descriptive, p values
are presented as raw values and not corrected for multiple
comparisons. For purposes of discussion and similar to
Orton et al. [5], multiple comparisons were accounted for by
adjusting the p value significance threshold by a correction
factor of 5. Thus statistically significant comparisons were
set at p < 0.05 (no correction) and highly significant compar-
isons at p < 0.01.
Results
Baseline assessment
Four patients opted out of the study prior to imaging, therefore
baseline analysis included 36 patients with unifocal malignant
lesions. Twenty-five lesions (69 %) were classified as mass
enhancement while 11 were non-mass-like lesions (31 %). All
lesions showed heterogeneous enhancement on DCE-MRI;
27 lesions (75 %) demonstrated a predominately type III en-
hancement curve while the rest (9/36, 25 %) showed type II
pattern. After surgery, 14 patients (39 %) showed pCR and 22
(61 %) were pNCR.
Prediction of response: pretreatment tumour characteristics
The mean tumour diameter was 4.7 cm (median 4.0 cm, range
1.2 − 12 cm). No significant difference was found between
responders (4.1 ± 0.4 cm) and non-responders (5.1 ± 0.5 cm,
p = 0.194).
According to IHC subtype, 33 % (12/36) were ER+PR+/
HER−, 33 % ER+PR+/HER2+, 3 % (1/36) ER−PR−/HER2+,
and 31 % (11/36) were categorised as TNBCs.
All but one patient in the triple-negative group showed
pCR, whereas 17 % (2/12) of both ER+PR+/HER2− and
ER+PR+/HER2+ tumours showed complete response.
Significant differences were observed between response
groups with respect to histological subtype (p < 0.001).
Prediction of response: pretreatment diffusion parameters
Pretreatment mean ADC, DDC and Dt values across the co-
hort were 1.11 × 10−3, 1.09 × 10−3 and 0.93 × 10−3 mm2/s re-
spectively. Figures 1 and 2 show representative images and
parametric maps of a complete responder. An example of the
mono-, bi- and stretched-exponential curves fitted to the data
from one pixel is illustrated in Fig. 3.
Table 3 shows the mean diffusion coefficients of the re-
sponse groups from all three models. Responders showed sig-
nificantly lower ADC, DDC and Dt values (0.92 ± 0.03, 0.93
± 0.04 and 0.85 ± 0.05 × 10−3mm2/s respectively) relative to
non-responders (1.20 ± 0.02, 1.25 ± 0.03 and 1.02 ±
0.05 × 10−3mm2/s respectively) (p < 0.01, p < 0.01, p = 0.02
respectively). The ƒ fraction showed higher fractions in re-
sponders; however, this was not significant (p = 0.09). On
subgroup analysis, ƒ was found to be significantly higher in
responders of the TNBC subtype (12.4 ± 4.1 % vs. 10.9 ±
1.2 %, p = 0.01).
Although lower α values were found in non-responders
compared to eventual responders, this was not significant
(0.81 ± 0.02 vs. 0.84 ± 0.02, p = 0.07).
Figure 4 shows the ROC curves comparing the diagnostic
efficacy of diffusion coefficients relative to pathological re-
sponse. DDC demonstrated a larger AUC (0.756, p = 0.01)
compared to ADC and Dt (0.749, p = 0.01 and 0.641,
p = 0.15 respectively). The DDC cut-off to differentiate re-
sponse groups on pretreatment MRI (1.141 × 10−3 mm2/s)
yielded the highest sensitivity (81 %) and specificity (72 %)
(Table 4).
Mid-treatment assessment
All patients attended a second MRI midway through treat-
ment; however, 14 patients were excluded for the following
reasons: patients opted out of the research examination (n = 3),
images were unusable as a result of suboptimal fat suppression
(n = 2), subjects not receiving the standard six cycles of che-
motherapy (n = 2), three patients did not proceed with the full
diffusion imaging sequence prior to surgery after NACT as
they found it intolerable. Additionally, four patients were ex-
cluded from analysis as their follow-up MRI was not
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performed in a timely manner at mid-therapy (post cycle 3).
These patients developed liver and kidney lesions that were
later found to be benign. Finally, 22 malignant lesions were
available for analysis on the midway examination. Eight pa-
tients (36 %) showed pCR and 14 (64 %) were pNCRs.
Prediction of response: change in tumour size
A significant difference was found in tumour size as re-
sponders showed a smaller mean tumour size (1.5 ± 0.2 cm
vs. 2.9 ± 0.5 cm, p < 0.05).
Fig. 2 Parametric maps of the bi-
exponential and stretched-
exponential models in the same
female patient as in Fig. 1: a
Dt = 0.80 ± 0.28 × 10
−3 mm2/s, b
ƒ = 11.8 ± 1.3 %, cDDC = 0.98 ±
0.12 × 10−3 mm2/s, d α = 0.84 ±
0.18. It should be noted that the α
values in tumours express the
intravoxel heterogeneity, whereas
the other maps show intervoxel
heterogeneity between tissues. At
histopathology, the lesion was
identified as a grade 3 invasive
ductal carcinoma of TNBC
subtype. The patient underwent
wide local excision of the lesion.
On the excision specimen, no
invasive components were seen
and the patient was considered a
complete pathological responder
to NACT
Fig. 1 Representative images
from pretreatment MRI of a 49-
year-old female patient with
cancer of the right breast: a axial
DW image showing hyperintense
tumour with restricted diffusion
on the b900 s/mm2 image. bADC
map was generated from two b
values (0, 900 s/mm2). ROI was
drawn on the primary lesion and
copied to the ADC map
(ADC = 0.92 ± 0.094 × 10−3
mm2/s)
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Prediction of response: change in diffusion parameters
An increase in the mean values of the diffusion coefficients
was observed after three cycles of chemotherapy, with the
percentage increase in ADC and DDC showing a statistically
significant difference between responders (49 % and 43 %)
and non-responders (21%, 32%, p = 0.03 and p = 0.04 respec-
tively). However the increase in Dt did not show a significant
difference between response groups (36 % vs. 23 %, p = 0.14).
Moreover, the decrease in ƒ fraction found in responders
(29 %) was substantially different from the increase in ƒ
observed in pNCR (5 %, p = 0.05). Responders also showed
a larger increase in α compared to pNCR (7 % vs. 5 %). This,
however, was not significant (p = 0.68) (Table 3). Figure 5
Table 3 Mean diffusion
parameters according to patient
outcome
Parameters Responders Non-responders p value
Baseline (n = 36)
ADC (×10−3mm2/s) 0.92 ± 0.03 1.20 ± 0.02 <0.01**
DDC (×10−3mm2/s) 0.93 ± 0.04 1.25 ± 0.03 <0.01**
α 0.84 ± 0.02 0.81 ± 0.02 0.07
Dt (×10
−3mm2/s) 0.85 ± 0.05 1.02 ± 0.05 0.02*
ƒ (%) 12.10 ± 2.02 10.32 ± 1.15 0.09
Mid-treatment (n = 22)
Parameters Responders (% change) Non-responders (% change) p value of %change
ADC (×10−3mm2/s) 1.52 ± 0.32 (↑49 %) 1.27 ± 0.18 (↑21 %) 0.03*
DDC (×10−3mm2/s) 1.51 ± 0.15 (↑43 %) 1.40 ± 0.12 (↑32 %) 0.04*
α 0.91 ± 0.07 (↑7 %) 0.86 ± 0.11 (↑5 %) 0.68
Dt (×10
−3mm2/s) 1.30 ± 0.14 (↑36 %) 1.28 ± 0.15 (↑23 %) 0.14
ƒ (%) 8.48 ± 1.54 (↓29 %) 10.53 ± 2.51 (↑5 %) 0.05
Baseline andmid-treatment values of the various parameters (units × 10−3 mm2 /s except where shown). Values in
parenthesis are the percentage change. P values using a two-tailed independent t test compared between response
groups. Significant statistics have p < 0.05, while highly significant statistics have p < 0.01 which includes a
correction for multiple comparisons). Unless otherwise indicated, data represent mean values ± standard deviation
(percentage change between pretreatment and mid-treatment values) of the mono-exponential (ADC), bi-
exponential (Dt, ƒ) and stretched-exponential (DDC, α) parameters
*Values show statistically significant differences
**Values show highly significant differences
Fig. 4 ROCs for the response prediction of the pretreatment diffusion
coefficients from the mono-exponential, bi-exponential and stretched-
exponential models. The DDC demonstrated the largest AUC (0.75,
p = 0.01) compared with ADC and Dt (0.74, p = 0.01 and 0.641,
p = 0.15 respectively). The cut-off to differentiate between response
groups on pretreatment MRI for DDC (1.141 × 10−3 mm2/s) yielded the
highest measures of accuracy (sensitivity 81 %, specificity 72 %)
Fig. 3 Mono-exponential (green), bi-exponential (blue) and stretched-
exponential curves (red) fitted to one pixel in a breast lesion in a
pretreatment scan
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shows the mean change in the diffusion coefficients between
response groups.
Repeatability of measurements
Overall parameters of the mono- and stretched-exponential
models showed excellent inter- and intrarater repeatability.
Bi-exponential parameters ranged from excellent to fair
(Table 5).
Model selection
A significant correlation was found between ADC and the
non-Gaussian diffusion coefficients (p < 0.001 for both). A
higher correlation, however, was observed between ADC
and DDC (r = 0.89) compared to ADC and Dt (r = 0.76).
The AICc from the ROI data showed that stretched-
exponential was the preferred model at baseline and mid-
treatment measurements, showing lower values (62.6 ± 8.2,
66.6 ± 9.2) compared to the mono-exponential and bi-
exponential models (baseline, 81.7 ± 9.4 and 82.9 ± 9.7;
mid-treatment, 85.6 ± 10.2 and 88.6 ± 11.6 respectively).
Discussion
It is generally accepted that highly proliferating malignant
breast lesions result in a packed cellular microstructure, show-
ing more restricted diffusion and decreased ADC [26].
However the choice of b value may affect the calculated mea-
surement, which is influenced by multiple pools diffusing at
different rates, confounding the assessment of tissue diffusiv-
ity [27]. Alternative diffusion models have been devised to
account for the more complex non-Gaussian diffusion behav-
iour of biological tissues in vivo. Le Bihan et al. have shown
that signal attenuation is not only a result of random micro-
scopic motion of water molecules influenced by cell density
but is also dependent on microperfusion within the voxel [6].
Fig. 5 Mean distribution of the
diffusion coefficients of the three
models before the start of
treatment and after three cycles of
chemotherapy in complete and
non-complete responders. There
is an overall increase in
parameters in both groups;
however, a larger increase is
noted in the ADC and DDC of
complete responders. When the
increase in mean values of ADC
and DDC were compared
between response groups at mid-
treatment, a significant difference
was observed; p = 0.03 and
p = 0.04 respectively. However,
the increase in Dt did not show
statistical significance between
response groups (p = 0.14). Error
bars represent the 95 %
confidence interval
Table 4 ROC analysis of the
various parameters (units × 10−3
mm2/s except where shown)
indicating the sensitivity and
specificity measures at the
respective cut-off values and their
significance levels
Parameter AUC Cut-off value (×10−3mm2/s) Sensitivity (%) Specificity (%) p value
ADC (×10−3mm2/s) 0.749 1.012 81 67 0.01*
DDC (×10−3mm2/s) 0.756 1.141 81 72 0.01*
Dt (×10
−3mm2/s) 0.641 0.967 71 53 0.15
α (unit-less) 0.644 0.838 60 47 0.14
ƒ (%) 0.637 11.01 66 43 0.16
Values show statistical significance of the pretreatment mono-exponential (ADC), bi-exponential (Dt, ƒ) and
stretched-exponential (DDC, α) parameters
AUC area under the curve
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This has become of particular interest, as tumour angiogenesis
is seen an important determinant in the outcome of patients.
Numerically, however, it has been shown that fitting three
parameters for the bi-exponential model can be unstable [28,
29]. In this study we assessed two non-Gaussian models ac-
quired at eight b values to capture the various diffusion prop-
erties of tissues and compared them with the mono-
exponential model using the standard b values commonly im-
plemented in DW-MRI of the breast.
Our baseline results were consistent with Sigmund et al.
showing lower Dt values compared to ADC [30]. This was
expected on exclusion of the perfusion effect, as the lower b
values were employed to capture the much higher pseudo-
diffusion. Furthermore, a strong correlation was found be-
tween the mono- and stretched-exponential diffusion coeffi-
cients. This suggests that DDC can be interpreted in the same
way as ADC with the observation of a continuous distribution
of diffusion components within the microenvironment.
Similar to Park et al. [31], our study also shows an inverse
correlation between tumour diffusion coefficients and thera-
peutic response, where substantially higher pretreatment
values of ADC, DDC, Dt and lower ƒ fractions were more
suggestive of necrotic, less viable lesions. These lesions have
often been found to be hypoxic, more aggressive and less
sensitive to chemotherapy [32].
The mean ƒ fraction of tumours was also able to differen-
tiate responders in the most biologically aggressive subtype
(TNBC), showing complete response in about one-third of
tumours, consistent with previous reports [33]. However, a
full statistical evaluation was not possible because of the small
sample size of the other subtypes.
Although the attribution of the diffusion index α to a bio-
logical correlate is still under investigation, lower values seen
in non-responsive lesions indicate a more heterogeneous mi-
croenvironment within the imaging voxels [19]. This param-
eter could in turn be viewed as a reflection of the microstruc-
tural complexity of the tissue, suggesting changes in the de-
gree of cellular pleomorphism, vascular heterogeneity and
presence of microscopic necrosis [13].
Although non-significant (p = 0.68), responders in our
study showed an increase in the structural homogeneity (α
closer to 1) at mid-treatment compared to non-responders.
These preliminary results are similar to those found by
Orton et al. in abdominal and pelvic tumours where changes
in α were substantially different between response groups
when assessed before the start of therapy, 7 days and 28 fol-
lowing treatment [5].
Neoadjuvant chemotherapy regimens used in the treatment
of breast cancer commonly consist of an anthracycline in com-
bination or sequentially administered with taxanes. The mech-
anism of action of anthracyclines is mainly attributed to the
inhibition of DNA synthesis, preventing the replication of
rapidly dividing cells [34], whereas taxanes have been report-
ed to have an anti-angiogenic effect with selective shutdown
of microvessel formation [35, 36]. This is supported by the
significant increase in DDC seen on mid-treatment (p = 0.04),
suggesting a change in the distribution of diffusion compart-
ments resulting from the early breakdown of the vascular en-
dothelial cells. On IVIM analysis, we also showed a large
decrease in the perfusion fraction in lesions showing complete
response, which is in contrast to its increase in lesions failing
to respond to treatment. This result is supported by previous
findings [37, 38].
When repeatability of measurements was assessed, the
mono- and stretched-exponential showed high ICC measures,
suggesting equivalent robustness of the derived parameters to
ADC. This is consistent with recent studies that have found
the stretched exponential equivalent to or outperforming other
models [5, 12, 16, 39].
This work suffered a few limitations. First, the chemother-
apy regimen in our population varied, which made it difficult
to draw specific conclusions on the biological effect of each
drug as detected by the diffusion models. However, this
should not have impacted the final response assessment as
the population received the same combination by the end of
NACT.
Second, although we evaluated the repeatability of the ROI
measurements, we did not perform validation studies. Orton
et al., however, showed that the parameters derived from the
stretched-exponential model are highly reproducible and
could potentially serve as quantitative biomarkers for response
assessment in abdominal and pelvic tumours [5].
In this study, we implemented the stretched-exponential
model using eight b values to characterise the deviation from
the Gaussian curve and compared it with the bi-exponential
model. Past studies have used 4−5 b values and produced
similar results [13, 14, 19], which affords the potential of
increased DW-MRI capability for characterising tissue prop-
erties over an extended b value range at reasonable scan times.
Finally, our study was limited by the small sample size with
differing rates of responders within the tumour subtypes.
However, we showed that the DW-MRI could be sensitive
to baseline and early treatment effects caused by NACT using
the DDC parameter of the stretched-exponential model, as
Table 5 Inter- and intraobserver repeatability measures of the diffusion
parameters using the intraclass correlation (ICC) metrics
Parameter Interobserver agreement Intraobserver agreement
ADC (×10−3mm2/s) 0.816 (0.657, 0.912) 0.910 (0.823, 0.954)
DDC (×10−3mm2/s) 0.789 (0.601, 0.898) 0.860 (0.725, 0.929)
Dt (×10
−3mm2/s) 0.699 (0.641, 0.859) 0.778 (0.756, 0.889)
α (unit-less) 0.808 (0.760, 0.938) 0.822 (0.648, 0.910)
ƒ (%) 0.605 (0.569, 0.868) 0.695 (0.531, 0.893)
Data represents intraclass correlation with 95 % confidence intervals
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demonstrated by the large AUC with satisfactory sensitivity
and specificity measures, and the ƒ fraction of the bi-
exponential model. Unlike in abdominal and pelvic tumours
[5], α did not differentiate between response groups in the
breast. This may relate to the timing of the follow-up MRI,
which was performed after the third cycle of NACT (i.e.
6 weeks of treatment). Therefore follow-up imaging at an
earlier time point may elucidate the change in α between
responders and non-responders.
In conclusion, this feasibility study showed that DW-MRI
is sensitive to baseline and early treatment changes in breast
cancer using non-mono-exponential models, which offer ad-
ditional imaging biomarkers that can potentially provide in-
sights into the cellular compartments and membranes and may
become more sensitive to treatment-induced tissue changes.
Our results show that the stretched-exponential model can
potentiallymonitor such changes. This data supports the wider
use of these models in assessing treatment effects beyond that
routinely measured with ADC.
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